Evaluation of the Tolerance of Afatinib in Combination With Docetaxel and Cisplatin in LAHNSCC Induction Chemotherapy

NCT02216617 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

HNSCC

Interventions

DRUG: Taxotere, Cisplatin, Afatinib

Sponsor

Groupe Oncologie Radiotherapie Tete et Cou